Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Acerus Pharmaceuticals Corp ASPCQ

Acerus Pharmaceuticals Corp is a specialty pharmaceutical company focused on the development, manufacture, marketing and distribution of branded products that improve patient experience, with a primary focus on the field of men's health. Its foundational product includes NATESTO, a testosterone therapy based on nasal gel technology. The company commercializes its products via its salesforce in... see more

OTCPK:ASPCQ - Post Discussion

Acerus Pharmaceuticals Corp > Final 48 hours: Here's your last chance to make an offer
View:
Post by PitchinPennies on Oct 24, 2022 11:43am

Final 48 hours: Here's your last chance to make an offer

Here at S-l-o-w Eddie's Unclaimed Drug Emporium, we've got to clear our shelves before Oct. 26 to make room for the next tenant.

Everything must go! We're selling out to the bare walls. No reasonable offer will be refused. So pick up the phone and call Michael Hayes right now at 416 575 9089. He's standing by to take your call.

User image
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities